Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA

To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in the USA. Patients with newly diagnosed HCC were identified from the MarketScan databases (1 July 2015–31 May 2018). The LRTs received and all-cause and HCC-related...

Full description

Saved in:
Bibliographic Details
Published inHepatic oncology Vol. 8; no. 3; p. HEP37
Main Authors Aly, Abdalla, Lingohr-Smith, Melissa, Lin, Jay, Seal, Brian
Format Journal Article
LanguageEnglish
Published London, UK Future Medicine Ltd 01.09.2021
Subjects
healthcare economic burden
hepatocellular carcinoma
locoregional therapies
treatment patterns
Online AccessGet full text

Cover

More Information
Summary:To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in the USA. Patients with newly diagnosed HCC were identified from the MarketScan databases (1 July 2015–31 May 2018). The LRTs received and all-cause and HCC-related healthcare costs were measured. Among 2101 patients with HCC, most received embolization therapy as their first LRT treatment (57.8%, n = 1215); 17.1% (n = 360) received ablative therapy and 8.7% (n = 182) radiation therapy; 16.4% (n = 344) received multiple LRTs. After patients received their first LRT treatment, total all-cause healthcare costs averaged $20,316 per patient per month; 70.7% ($14,359) were HCC related. Among newly diagnosed HCC patients treated with LRT in the USA, the economic burden is high.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-0923
2045-0931
DOI:10.2217/hep-2021-0001